Ligand Pharmaceuticals LGND Payments for finance leases
Payments for finance leases at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeasePrincipalPayments.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's payments for finance leases.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's payments for finance leases?
- Ligand Pharmaceuticals (LGND) reported payments for finance leases of $7K in Q1 2026.
- How has Ligand Pharmaceuticals's payments for finance leases changed year-over-year?
- Ligand Pharmaceuticals's payments for finance leases decreased by 0.0% year-over-year, from $7K to $7K.
- What is the long-term trend for Ligand Pharmaceuticals's payments for finance leases?
- Over 3 years (2022 to 2025), Ligand Pharmaceuticals's payments for finance leases has grown at a -20.6% compound annual growth rate (CAGR), from $54K to $27K.
- What does payments for finance leases mean?
- Principal payments on finance lease obligations, reducing the lease liability on the balance sheet.